Oncotelic Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk.

The company’s approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities. The company is also pursuing a platform-based model through Deciparticle and its AI-enhanced PDAOAI biomedical infrastructure initiative, positioning itself at the intersection of oncology, nanomedicine and artificial intelligence.

Growing investor interest in scalable healthcare platforms has coincided with expansion across related sectors, including advanced drug-delivery systems and AI-driven healthcare innovation. Oncotelic joins a group of companies advancing platform-oriented strategies, including Northwest Biotherapeutics (OTCQB: NWBO), Sangamo Therapeutics (OTCQB: SGMO), HIVE Digital Technologies (NASDAQ: HIVE) and Iovance Biotherapeutics (NASDAQ: IOVA).

To view the full press release, visit https://ibn.fm/EU38X.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The Company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The Company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics.

The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.